{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:46:20Z","timestamp":1784119580628,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","jpeds.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jpeds.2024.113913","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:25:52Z","timestamp":1704990352000},"page":"113913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection"],"prefix":"10.1016","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-8612","authenticated-orcid":false,"given":"Chien-Chung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chou","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Ming-Chih","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyin","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2024.113913_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jpeds.2024.113913_bib2","doi-asserted-by":"crossref","first-page":"e186801","DOI":"10.1001\/jamanetworkopen.2018.6801","article-title":"Prevalence of severe visual disability among preterm children with retinopathy of prematurity and association with adherence to best practice guidelines","volume":"2","author":"Norman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpeds.2024.113913_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2004-1413","article-title":"The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study","volume":"116","author":"Good","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2024.113913_bib4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1167\/iovs.18-24020","article-title":"Retinopathy of prematurity trends in Taiwan: a 10-year nationwide population study","volume":"59","author":"Kang","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jpeds.2024.113913_bib5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity. The cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpeds.2024.113913_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26229-4","article-title":"Risk factors associated with retinopathy of prematurity development and progression","volume":"12","author":"de Las Rivas Ram\u00edrez","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpeds.2024.113913_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12886-022-02591-9","article-title":"Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants","volume":"22","author":"Yucel","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: a review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib9","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"EtfRoPC","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.earlhumdev.2007.11.007","article-title":"Treatment of retinopathy of prematurity","volume":"84","author":"Clark","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.jpeds.2024.113913_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2024.113913_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0040-1713181","article-title":"Update in the treatment of retinopathy of prematurity","volume":"39","author":"Bancalari","year":"2022","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jpeds.2024.113913_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3345\/cep.2021.00773","article-title":"Retinopathy of prematurity: a review of epidemiology and current treatment strategies","volume":"65","author":"Hong","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.jpeds.2024.113913_bib14","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.3390\/ijms23158529","article-title":"New aspects on the treatment of retinopathy of prematurity: currently available therapies and emerging novel therapeutics","volume":"23","author":"Ryu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpeds.2024.113913_bib15","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3928\/23258160-20170428-01","article-title":"Letter to the editor: very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"48","author":"Mataftsi","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib19","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, Third Edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpeds.2024.113913_bib20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol"},{"key":"10.1016\/j.jpeds.2024.113913_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14767058.2021.1888913","article-title":"Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?","volume":"35","author":"Celik","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.jpeds.2024.113913_bib22","article-title":"Ocular adverse effects of intravitreal bevacizumab are potentiated by Intermittent hypoxia in a rat model of oxygen-induced retinopathy","volume":"2017","author":"Tan","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib23","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2024.113913_bib24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1164\/rccm.201812-2348OC","article-title":"The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach","volume":"200","author":"Jensen","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2024.113913_bib25","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpeds.2024.113913_bib26","first-page":"Cd009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpeds.2024.113913_bib27","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2024.113913_bib28","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J AAPOS"},{"key":"10.1016\/j.jpeds.2024.113913_bib30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaapos.2021.02.004","article-title":"Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report","volume":"25","author":"Taylor","year":"2021","journal-title":"J AAPOS"},{"key":"10.1016\/j.jpeds.2024.113913_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpeds.2024.113913_bib33","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpeds.2024.113913_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fphar.2015.00248","article-title":"Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach","volume":"6","author":"Platania","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpeds.2024.113913_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib36","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpeds.2024.113913_bib39","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jpeds.2024.113913_bib40","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/aos.14852","article-title":"Ranibizumab in retinopathy of prematurity\u2014one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study","volume":"100","author":"Stahl","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib41","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.jpeds.2024.113913_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18240\/ijo.2023.01.14","article-title":"Recurrence risk factors of intravitreal ranibizumab monotherapy in retinopathy of prematurity: a retrospective study at one center","volume":"16","author":"Wu","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib44","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jpeds.2024.113913_bib45","article-title":"Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jpeds.2024.113913_bib46","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.4103\/1673-5374.219034","article-title":"Pathophysiology of periventricular leukomalacia: what we learned from animal models","volume":"12","author":"Zaghloul","year":"2017","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.jpeds.2024.113913_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13020291","article-title":"Systemic cytokines in retinopathy of prematurity","volume":"13","author":"Wu","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.jpeds.2024.113913_bib48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00431-014-2437-9","article-title":"Hemodynamic alterations recorded by electrical cardiometry during ligation of ductus arteriosus in preterm infants","volume":"174","author":"Lien","year":"2015","journal-title":"Eur J Pediatr"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347624000167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347624000167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T01:15:58Z","timestamp":1739236558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347624000167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":48,"alternative-id":["S0022347624000167"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2024.113913","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Risk Factors for Retinopathy of Prematurity Reactivation after Intravitreal Antivascular Endothelial Growth Factor Injection","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2024.113913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113913"}}